This funding opportunity supports research and preclinical development of highly efficacious vaccines against malaria by leveraging recent advances in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to develop long-lasting, highly effective protection that can save lives and serve as a model for other mosquito-borne diseases. Clinical trials are not allowed under this funding mechanism.
Eligible applicants include a wide range of U.S. government entities, educational institutions, nonprofits, for-profit organizations, small businesses, and foreign organizations. Foreign subawards/subcontracts are not allowed, but foreign components and collaborations without subawards are permitted
